Targeted drugs for KRAS G12C colorectal cancer in frail patients
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (panitumumab and sotorasib) with a common IV chemo (5-fluorouracil) as a first treatment for people with a specific type of advanced colorectal cancer who cannot tolerate stronger chemo. It offers a gentler option that may be more effective than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced colorectal cancer that cannot be removed by surgery, with a specific KRAS G12C mutation (a gene change).
- Your general health and daily activity level must be reduced (WHO performance status 2), or you are between 70–75 with mild symptoms, or you are 75 or older.
- You must have not yet received any treatment for cancer that has spread (previous chemo for early-stage cancer is okay if it ended more than 6 months ago).
- You must have adequate blood counts and kidney/liver function (your doctor will test these).
- You must be willing to give blood and a tumor sample for genetic studies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
This trial tests a new combination of drugs (sotorasib, panitumumab, and FOLFIRI) against the standard treatment for colorectal cancer that has spread. It's for people whose tumor has a specific KRAS G12C mutation and who have not had chemotherapy before for advanced disease.
This trial tests three drugs (adagrasib, cetuximab, cemiplimab) together for colorectal cancer with a KRAS G12C mutation. The goal is to see if this combination shrinks tumors or slows cancer growth.
This trial tests a combination of two drugs (fulzerasib and cetuximab) given before surgery to shrink locally advanced colorectal cancer that has a specific genetic mutation called KRAS G12C. The goal is to help make the cancer easier to remove surgically and improve outcomes.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This trial tests a new targeted pill, VS-7375, for people with a specific type of advanced colorectal cancer called KRAS G12D. It's for those who either haven't had treatment yet or whose cancer has worsened after prior therapy.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.